natgillin/translations-raw huggingface dataset:
For patients undergoing angioplasty (Percutaneous coronary intervention)
Za bolnike, pri katerih so opravili angioplastiko (perkutano koronarno intervencijo)
For patients undergoing major hip surgery, a treatment duration of 5 weeks is recommended.
Po velikem kirurškem posegu na kolku se priporoča 5 tedenska zaščita.
For patients undergoing major knee surgery, a treatment duration of 2 weeks is recommended.
Po velikem kirurškem posegu na kolenu se priporoča 2 tedenska zaščita.
For patients undergoing PCI, bivalirudin MUST be administered initially as an intravenous bolus followed immediately by an infusion.
Bolnikom med PCI je treba bivalirudin najprej dati kot intravenski bolus, ki mu takoj sledi infuzija.
For patients up to 84 kg calculate the volume required to be administered according to the formula below:
Za bolnike s telesno maso do 84 kg izračunajte potrebni volumen v skladu s spodnjo preglednico:
For patients up to 84 kg calculate the volume required to be administered according to the formula below:
Za bolnike s telesno maso do 84 kg izračunajte potrebno količino v skladu s spodnjo preglednico:
For patients using concomitant and anti-platelet medication, haemorrhagic adverse events were reported in a slightly higher proportion of patients injected with OZURDEX (up to 29%) compared with the sham group (up to 23%), irrespective of indication or number of treatments.
Pri bolnikih, ki so hkrati prejemali zdravljenje z antitrombotiki, so o neželenih dogodkih s krvavitvijo poročali pri nekoliko večjem odstotku bolnikov, ki so jim injicirali zdravilo OZURDEX (do 29 %), kot v kontrolni skupini (do 23 %), ne glede na indikacije ali število zdravljenj.
For patients well managed on deferoxamine
za bolnike, ki so dobro urejeni z deferoksaminom
For patients who achieve tri-lineage response, including transfusion independence, lasting at least 8 weeks: the dose of eltrombopag may be reduced by 50%.
Bolnikom, ki dosežejo odziv pri vseh treh linijah krvnih celic in so pri tem neodvisni od transfuzij in pri katerih ta odziv traja najmanj 8 tednov, je mogoče odmerek eltrombopaga zmanjšati za 50 %.
For patients who are dosed initially at 10 mg and who experience thrombocytopenia or neutropenia:
Za bolnike, ki so prejeli začetni odmerek 10 mg in pri katerih se pojavi trombocitopenija ali nevtropenija:
For patients who are dosed initially at docetaxel 75 mg/m2 in combination with cisplatin and whose nadir of platelet count during the previous course of therapy is < 25,000 cells/mm3, or in patients who experience febrile neutropenia, or in patients with serious non-haematologic toxicities, the docetaxel dose in subsequent cycles should be reduced to 65 mg/m2.
Bolnikom, ki uvodoma dobijo docetaksel v odmerku 75 mg/m2 v kombinaciji s cisplatinom in imajo v predhodnem ciklusu zdravljenja najmanjše število trombocitov < 25.000 celic/mm3, bolnikom, ki doživijo febrilno nevtropenijo, in bolnikom z resnimi nehematološkimi toksičnimi učinki je treba odmerek docetaksela v naslednjih ciklusih zmanjšati na 65 mg/m2.
For patients who are dosed initially at docetaxel 75 mg/m2 in combination with cisplatin and whose nadir of platelet count during the previous course of therapy is < 25,000 cells/mm3, or in patients who experience febrile neutropenia, or in patients with serious non-haematologic toxicities, the docetaxel dose in subsequent cycles should be reduced to 65 mg/m2.
Bolnikom, ki uvodoma dobijo docetaksel v odmerku 75 mg/m2 v kombinaciji s cisplatinom in imajo v predhodnem krogu zdravljenja najmanjše število trombocitov < 25.000 celic/mm3, bolnikom, ki doţivijo febrilno nevtropenijo, in bolnikom z resnimi nehematološkimi toksičnimi učinki je treba odmerek docetaksela v naslednjih krogih zmanjšati na 65 mg/m2.
For patients who are dosed initially at docetaxel 75 mg/m2 in combination with cisplatin and whose nadir of platelet count during the previous course of therapy is <25,000 cells/mm3, or in patients who experience febrile neutropenia, or in patients with serious non-haematologic toxicities, the docetaxel dose in subsequent cycles should be reduced to 65 mg/m2.
Bolnikom, ki uvodoma dobijo docetaksel v odmerku 75 mg/m2 v kombinaciji s cisplatinom in imajo v predhodnem ciklusu zdravljenja najmanjše število trombocitov < 25.000 celic/mm3, bolnikom, ki doživijo febrilno nevtropenijo, in bolnikom z resnimi nehematološkimi toksičnimi učinki je treba odmerek docetaksela v naslednjih ciklusih zmanjšati na 65 mg/m2.
For patients who are dosed initially at docetaxel 75 mg/m2 in combination with cisplatin and whose nadir of platelet count during the previous course of therapy is <25,000 cells/mm3, or in patients who experience febrile neutropenia, or in patients with serious non-haematologic toxicities, the docetaxel dose in subsequent cycles should be reduced to 65 mg/m2.
Bolnikom, ki uvodoma dobijo docetaksel v odmerku 75 mg/m2 v kombinaciji s cisplatinom in imajo v predhodnem krogu zdravljenja najmanjše število trombocitov < 25.000 celic/mm3, bolnikom, ki doživijo febrilno nevtropenijo, in bolnikom z resnimi nehematološkimi toksičnimi učinki je treba odmerek docetaksela v naslednjih krogih zmanjšati na 65 mg/m2.
For patients who are exposed to sun, protective clothing, and use of sun screen is advisable.
Za bolnike, ki so izpostavljeni soncu, so priporočljivi zaščitna oblačila in uporaba zaščitnih sredstev pred soncem.
For patients who are exposed to sun, protective clothing, and/or use of sun screen (e.g. mineral-containing) may be advisable.
Za bolnike, ki so izpostavljeni soncu, je verjetno koristna uporaba zaščitnih oblačil in/ali zaščitne kreme (npr. na osnovi mineralov).
For patients who are initiating a combination of Betmiga and digoxin, the lowest dose for digoxin should be prescribed initially.
Bolnikom, ki začenjajo s sočasno uporabo zdravila Betmiga in digoksina, je treba uvodoma predpisati najmanjši odmerek digoksina.
For patients who are prescribed a full 40 mg dose of Humira, a 40 mg pen and a 40 mg prefilled syringe are also available for use.
Bolniki s predpisanim odmerkom zdravila Humira 40 mg imajo na voljo injekcijski peresnik s 40 mg adalimumaba in napolnjeno brizgo s 40 mg adalimumaba.
For patients who are taking
Pri bolnikih, ki se zdravijo s
For patients who are taking tenofovir disoproxil fumarate, if REYATAZ/ritonavir with both tenofovir disoproxil fumarate and an H2-receptor antagonist are co-administered, a dose increase of REYATAZ to 400 mg with 100 mg of ritonavir is recommended.
Pri bolnikih, ki se zdravijo z dizoproksiltenofovirat fumaratom: če se sočasno uporablja zdravilo REYATAZ/ritonavir v kombinaciji z obema, dizoproksiltenofovirat fumaratom in antagonistom histaminskih receptorjev H2, je priporočljivo, da se odmerek zdravila REYATAZ poveča na 400 mg in uporablja skupaj z ritonavirjem v odmerku 100 mg.
For patients who are taking tenofovir, if REYATAZ/ritonavir with both tenofovir and an H2-receptor antagonist are co-administered,a dose increase of REYATAZ to 400 mg with 100 mg of ritonavir is recommended.
Pri bolnikih, ki se zdravijo s tenofovirjem: če se sočasno uporablja zdravilo REYATAZ/ritonavir v kombinaciji z obema, tenofovirjem in antagonistom histaminskih receptorjev H2, je priporočljivo, da se odmerek zdravila REYATAZ poveča na 400 mg in uporablja skupaj z ritonavirjem v odmerku 100 mg.
For patients who are unable to swallow capsules, the content of the capsules may be dispersed in a teaspoon of apple puree and taken immediately.
Pri bolnikih, ki kapsul ne morejo pogoltniti, se lahko njena vsebina raztopi v čajni žlički jabolčne kaše in takoj zaužije.
For patients who are unable to swallow tablets or who weigh less than 50 kg or whose body surface area is below 1.25 m2 according to the Mosteller formula, other nevirapine containing oral formulations are available and should be used if appropriate.
Za bolnike, ki ne morejo pogoltniti tablet, tehtajo manj kot 50 kg ali katerih telesna površina po Mostellerjevi formuli je manj kot 1,25 m2, so na voljo tudi druge peroralne farmacevtske oblike, ki vsebujejo nevirapin in jih uporabite, če je primerno.
For patients who are unable to swallow the capsules or tablets, Stocrin can be given using the oral solution.
Pri bolnikih, ki kapsul ali tablet ne morejo pogoltniti, se zdravilo Stocrin lahko daje kot peroralna raztopina.
For patients who are unable to swallow the tablet whole, the Moventig tablet can be crushed to a powder and mixed in half a glass of water (120 ml) and drunk immediately.
Bolniki, ki tablete ne morejo pogoltniti cele, lahko tableto Moventig zdrobijo v prašek, ki ga zmešajo s pol kozarca vode (120 ml) in takoj popijejo.
For patients who are unable to swallow the tablets, Intelence tablets can
Bolniki, ki tablet zdravila Intelence ne
For patients who are unable to swallow whole tablets, Adempas tablets may be crushed and mixed with water or soft foods such as applesauce immediately prior to use and administered orally (see section 5.2).
Za bolnike, ki ne morejo požirati celih tablet, se lahko tablete zdravila Adempas tik pred uporabo zdrobijo in zmešajo z vodo ali mehko hrano, kot je na primer jabolčna čežana, ter dajo peroralno (glejte poglavje 5.2).
For patients who are unable to swallow whole tablets, Xarelto tablet may be crushed and mixed with water or apple puree immediately prior to use and administered orally.
Pri bolnikih, ki cele tablete ne morejo pogoltniti, se lahko tableta zdravila Xarelto tik pred peroralno uporabo zdrobi in premeša z vodo ali jabolčno čežano.
For patients who are unable to swallow, the capsule contents can be mixed with a small amount of food (around two teaspoons).
Pri bolnikih, ki zdravila ne morejo pogoltniti, se lahko vsebina kapsule zmeša z majhno količino hrane (približno dvema čajnima žličkama).
For patients who can swallow liquids take RAVICTI should be taken orally, even those with a nasogastric and/or gastrostomy tube.
Bolniki, ki lahko pogoltnejo tekočino, morajo zaužiti zdravilo RAVICTI peroralno, to velja tudi za bolnike z nazogastrično sondo in/ali gastrostomo.
For patients who cannot swallow the whole capsule, the gastro-resistant hard capsule may be opened and the contents may be sprinkled on food (such as apple compote or berry jelly) or mixed in with an acidic drink (such as orange juice or any acidic juice).
Za bolnike, ki ne morejo pogoltniti cele kapsule, lahko gastrorezistentno trdo kapsulo odprete in vsebino stresete na obrok hrane (na primer jabolčni kompot ali jagodni žele) ali vmešate v kislo pijačo (na primer pomarančni sok ali drug kisli sadni sok).
For patients who cannot take oral medication, dimercaprol administered at a dose of 3 mg/kg intramuscularly every 4 hours until any immediately life-threatening toxicity has subsided may be considered.
Pri pacientih, ki zdravil ne morejo jemati peroralno, se lahko uporabi dimerkaprol v odmerku 3 mg/kg intramuskularno vsake 4 ure do upada življenjsko nevarne toksičnosti.
For patients who develop Grade ≥ 3 toxicities including hypertension, hypokalaemia, oedema and other non-mineralocorticoid toxicities, treatment should be withheld and appropriate medical management should be instituted.
Pri bolnikih s stopnjo toksičnosti ≥ 3, vključno s hipertenzijo, hipokaliemijo, edemom in drugimi nemineralkortikoidnimi toksičnostmi, je treba zdravljenje prekiniti in uvesti primerno zdravljenje.
For patients who develop hepatotoxicity during treatment, suspension of treatment and dose adjustment may be required (see sections 4.2 and 4.4).
Bolnikom, pri katerih med zdravljenjem pride do hepatotoksičnosti, je treba začasno prekiniti zdravljenje in prilagoditi odmerjanje (glejte poglavji 4.2 in 4.4).
For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the condition.
Kirurški posegi v ustni votlini lahko poslabšajo stanje bolnikov, ki se jim med zdravljenjem z difosfonatom pojavi osteonekroza čeljustnic.
For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the condition.
Pri bolnikih, pri katerih se med zdravljenjem z difosfonati razvije osteonekroza čeljusti, utegne stomatološka operacija stanje poslabšati.
For patients who develop severe hypertension, temporarily interrupt axitinib and restart at a lower dose once the patient is normotensive.
Pri bolnikih, pri katerih pride do zelo izrazite hipertenzije, je treba zdravljenje z aksitinibom začasno prekiniti in ga ponovno uvesti z manjšim odmerkom potem, ko se krvni tlak pri bolniku normalizira.
For patients who dose escalated from eow to weekly regimen, the mean (±SD) serum concentrations of adalimumab at Week 52 were 15.3 ± 11.4 μg/ml (40/20 mg, weekly) and 6.7 ± 3.5 μg/ml (20/10 mg, weekly).
Pri bolnikih, ki so prešli iz režima vsak drugi teden na režim vsak teden, so bile srednje (±SD) serumske koncentracije adalimumaba v 52.tednu 15,3 ± 11,4 μg/ml (40/20 mg, tedensko) in 6,7 ± 3,5 μg/ml (20/10 mg, tedensko).
For patients who dose escalated from eow to weekly regimen, the mean (±SD) serum concentrations of adalimumab at Week 52 were 15.3±11.4 μg/mL (40/20 mg, weekly) and 6.7±3.5 μg/mL (20/10 mg, weekly).
Pri bolnikih, ki so prešli iz režima vsak drugi teden na režim vsak teden, so bile srednje (±SD) serumske koncentracije adalimumaba v 52. tednu 15,3 ± 11,4 μg/ml (40/20 mg, tedensko) in 6,7 ± 3,5 μg/ml (20/10 mg, tedensko).
For patients who dose escalated from eow to weekly regimen, the mean (±SD) serum concentrations of adalimumab at Week 52 were 15.3±11.4 μg/mL (40/20 mg, weekly) and 6.7±3.5 μg/mL (20/10 mg, weekly).
Pri bolnikih, ki so prešli iz režima vsak drugi teden na režim vsak teden, so bile srednje (±SD) serumske koncentracije adalimumaba v 52.tednu 15,3 ± 11,4 μg/ml (40/20 mg, tedensko) in 6,7 ± 3,5 μg/ml (20/10 mg, tedensko).
For patients who experience Grade 3 or 4 diarrhoea, the dose should be reduced by 0.4 mg/m2/day for subsequent courses (see section 4.4).
Pri bolnikih z drisko stopnje 3 ali 4 je potrebno odmerek zmanjšati za 0,4 mg/m2/dan pri pri naslednjih ciklusih (glejte poglavje 4.4).
For patients who experience progressive anorexia, asthenia and weight decrease within a relatively short period of time, a general medical evaluation including liver function should be considered.
Za bolnike, ki izkusijo progresivno anoreksijo, astenijo ali zmanjšanje telesne mase v relativno kratkem obdobju je treba razmisliti o splošnem zdravniškem pregledu, vključno z delovanjem jeter.
For patients who experience progressive anorexia, asthenia and weight decrease within a relatively short period of time, a general medical evaluation including liver function should be considered.
Za bolnike, ki izkusijo progresivno anoreksijo, astenijo ali zmanjšanje telesne mase v relativno kratkem obdobju, je treba razmisliti o splošnem zdravniškem pregledu, vključno z delovanjem jeter.
For patients who experienced somnolence the responder rates were 48% on pregabalin and 16% on placebo.
Od bolnikov, ki so izkusili somnolenco, jih je poročalo o izboljšanju 48%, ki so prejemali pregabalin, in 16%, ki so prejemali placebo.
For patients who have had a hip or knee replacement, treatment with Eliquis should be started 12 to 24 hours after the operation.
Pri bolnikih, ki so prestali operativno vstavitev umetnega kolena ali kolka naj se zdravljenje z zdravilom Eliquis začne 12 do 24 ur po operaciji.
For patients who have had a hip or knee replacement, treatment with Pradaxa should start with one 110 mg capsule taken one to four hours
Pri bolnikih po kirurški zamenjavi kolka ali kolena se mora zdravljenje z zdravilom Pradaxa pričeti z eno 110-miligramsko kapsulo, ki jo bolnik vzame eno do štiri ure po koncu operacije.
For patients who have resided in or travelled to regions where invasive fungal infections such as histoplasmosis, coccidioidomycosis, or blastomycosis are endemic, the benefits and risks of Inflectra treatment should be carefully considered before initiation of Inflectra therapy.
Pri bolnikih, ki so živeli ali potovali v kraje, kjer so endemične invazivne glivične okužbe, kot so histoplazmoza, kokcidioidomikoza ali blastomikoza, je treba skrbno pretehtati koristi in tveganja zdravljenja z zdravilom Inflectra, preden bolniku uvedete to zdravilo.
For patients who have resided in or travelled to regions where invasive fungal infections such as histoplasmosis, coccidioidomycosis, or blastomycosis are endemic, the benefits and risks of Remsima treatment should be carefully considered before initiation of Remsima therapy.
Pri bolnikih, ki so živeli ali potovali v kraje, kjer so endemične invazivne glivične okužbe, kot so histoplazmoza, kokcidioidomikoza ali blastomikoza, je treba skrbno pretehtati koristi in tveganja zdravljenja z zdravilom Remsima, preden bolniku uvedete to zdravilo.
For patients who have resided in or travelled to regions where invasive fungal infections such as histoplasmosis, coccidioidomycosis, or blastomycosis are endemic, the benefits and risks of Simponi treatment should be carefully considered before initiation of Simponi therapy.
Pri bolnikih, ki so potovali v kraje, kjer so invazivne glivne okužbe, kot so histoplazmoza, kokcidioidomikoza ali blastomikoza, oziroma so živeli v takšnih krajih, je treba pred uvedbo zdravljenja z zdravilom Simponi skrbno pretehtati koristi in tveganja zdravljenja s tem zdravilom.
For patients who have taken medicines to treat HIV infection before, doctors should only prescribe Viread once they have looked at the antiviral medicines the patient has taken before or the likelihood of the virus’s response to antiviral medicines.
Bolnikom, ki so predhodno že jemali zdravila za zdravljenje okužbe z virusom HIV, smejo zdravniki predpisati zdravilo Viread šele potem, ko se seznanijo s protivirusnimi zdravili, ki jih je bolnik jemal pred tem, oziroma ko ocenijo, kakšna je verjetnost, da se bo virus odzval na protivirusna zdravila.
For patients who have taken medicines to treat their HIV infection before and failed to respond to that treatment, doctors should only prescribe Emtriva once they have looked at the antiviral medicines the patient has taken before and assessed the likelihood of the virus’s response to any new antiviral medicines that might be prescribed.
Bolnikom, ki so že jemali zdravila za zdravljenje okužbe s HIV, a se na to vrsto zdravljenja niso odzvali, lahko zdravniki predpišejo zdravilo Emtriva šele, ko pregledajo, katera zdravila je bolnik jemal prej in ocenijo verjetnost za odziv virusa na zdravljenje s katerimi koli novimi zdravili, ki bi jih utegnil predpisati.
For patients who may require a lower buprenorphine dose, buprenorphine 0.4 mg may be used.
Pri bolnikih, ki lahko potrebujejo manjši odmerek buprenorfina, lahko uporabite buprenorfin 0,4 mg.
For patients who never received Firazyr previously, the first treatment should be given in a medical institution or under the guidance of a physician.
Pri bolnikih, ki še nikoli niso prejeli zdravila Firazyr, je treba prvo injiciranje opraviti v zdravstveni ustanovi ali pod zdravnikovim nadzorom.
For patients who received only INVANZ, the most common adverse reactions reported during therapy plus follow-up for 14 days after treatment was stopped were: diarrhoea (5.2 %) and infusion site pain (6.1 %).
Pri bolnikih, ki so se zdravili samo z zdravilom INVANZ, so bili najpogosteje poročani neželeni učinki med zdravljenjem in v 14-dnevnem obdobju spremljanja po koncu zdravljenja naslednji: driska (5,2 %) in bolečina na vbodnem mestu infuzije (6,1 %).
For patients who received only INVANZ, the most frequently reported laboratory abnormalities and their respective incidence rates during therapy plus follow-up for 14 days after treatment was stopped were: elevations in ALT (4.6 %), AST (4.6 %), alkaline phosphatase (3.8 %) and platelet count (3.0 %).
Pri bolnikih, ki so prejemali samo zdravilo INVANZ, so med zdravljenjem in v 14-dnevnem obdobju spremljanja po koncu zdravljenja najpogosteje poročali o naslednjih laboratorijskih nepravilnostih: dvig ALT ( 4,6 %), AST (4,6 %), alkalne fosfataze (3,8 %) in števila trombocitov (3,0 %).
For patients who recently have lost body fluids e.g. through vomiting or diarrhoea, or by taking water tablets, your doctor may recommend a lower starting dose of 20 mg once a day.
Če ste pred kratkim izgubili več telesnih tekočin, npr. zaradi bruhanja, driske ali zaradi zdravil za odvajanje vode, vam bo zdravnik morda priporočil nižji začetni odmerek 20 mg enkrat na dan.
For patients who require further doses, there should be an interval of at least 12 weeks between two doses of Ilaris.
Pri bolnikih, ki potrebujejo dodaten odmerek, mora med dvema odmerkoma zdravila Ilaris preteči vsaj 12 tednov.
For patients who require use of corticosteroids, prophylaxis of PCP should be considered based upon current standard of care.
Pri bolnikih, ki potrebujejo uporabo kortikosteroidov, je treba v skladu z veljavnimi smernicami razmisliti o profilaksi proti pljučnici zaradi PCP.
For patients who responded to treatment, the median time to response was 11.9 weeks and the median duration of response was 58.7 weeks as per independent review (VEG105192).
Neodvisna presoja je pokazala, da je bila pri bolnikih, ki so se odzvali na zdravljenje, mediana vrednost časa do odziva 11,9 tednov, mediana vrednost trajanja odziva pa 58,7 tednov (VEG105192).
For patients who start treatment with 60 mg/m2 ONIVYDE and do not dose escalate to 80 mg/m2, the recommended first dose reduction is to 50 mg/m2 and the second dose reduction is to 40 mg/m2.
Pri bolnikih, ki se začnejo zdraviti z odmerkom 60 mg/m2 zdravila ONIVYDE in pri katerih odmerka ne povečamo na 80 mg/m2, je prvo priporočeno zmanjšanje odmerka na 50 mg/m2, drugo zmanjšanje odmerka pa na 40 mg/m2.
For patients who stayed on their randomised therapy, the mean (±SD) adalimumab trough concentrations at Week 52 were 9.5 ± 5.6 g/ml for the Standard Dose group and 3.5 ± 2.2 g/ml for the Low Dose group.
Pri bolnikih, ki so ostali na njihovi randomizirani terapiji, so bile srednje najmanjše koncentracije adalimumaba v 52.tednu 9,5 ± 5,6 μg/ml v skupini s standardnim odmerkom in 3,5 ± 2,2 μg/ml v skupini z majhnim odmerkom.
For patients who stayed on their randomised therapy, the mean (±SD) adalimumab trough concentrations at Week 52 were 9.5±5.6 g/mL for the Standard Dose group and 3.5±2.2 g/mL for the Low Dose group.
Pri bolnikih, ki so ostali na njihovi randomizirani terapiji, so bile srednje najmanjše koncentracije adalimumaba v 52. tednu 9,5 ± 5,6 μg/ml v skupini s standardnim odmerkom in 3,5 ± 2,2 μg/ml v skupini z majhnim odmerkom.
For patients who stayed on their randomised therapy, the mean (±SD) adalimumab trough concentrations at Week 52 were 9.5±5.6 g/mL for the Standard Dose group and 3.5±2.2 g/mL for the Low Dose group.
Pri bolnikih, ki so ostali na njihovi randomizirani terapiji, so bile srednje najmanjše koncentracije adalimumaba v 52.tednu 9,5 ± 5,6 μg/ml v skupini s standardnim odmerkom in 3,5 ± 2,2 μg/ml v skupini z majhnim odmerkom.
For patients who stayed on their randomised therapy, the mean (±SD) adalimumab trough concentrations at Week 52 were 9.5±5.6g/mL for the Standard Dose group and 3.5±2.2 g/mL for the Low Dose group.
Pri bolnikih, ki so ostali na njihovi randomizirani terapiji, so bile srednje najmanjše koncentracije adalimumaba v 52.tednu 9,5 ± 5,6 μg/ml v skupini s standardnim odmerkom in 3,5 ± 2,2 μg/ml v skupini z majhnim odmerkom.
For patients who test positive for HBV infection, consultation with a physician with expertise in the treatment of hepatitis B is recommended.
Pri tistih bolnikih, ki imajo pozitiven izvid na okužbo z virusom HBV, je priporočljiv posvet z zdravnikom, ki je strokovnjak za zdravljenje hepatitisa B.
For patients who test positive for HBV infection, consultation with a physician with expertise in the treatment of hepatitis B is recommended.
Za bolnike, ki so pozitivni na okužbo s HBV, je priporočljivo posvetovanje z zdravnikom, ki ima izkušnje z zdravljenjem hepatitisa B.
For patients who were not previously taking antiviral agents, Invirase should be started at 500 mg two times daily with ritonavir 100 mg two times daily for the first 7 days of treatment.
Pri bolnikih, ki predhodno niso jemali protivirusnih zdravil, je treba prvih sedem dni zdravljenja začeti jemati 500 mg zdravila Invirase dvakrat na dan skupaj s 100-miligramskim ritonavirjem dvakrat na dan.